Inovio Pharmaceuticals (NASDAQ: INO) is a pharmaceutical company using immunotherapy to fight against cancer and infectious diseases. It is the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. The company is focused on advancing a growing preclinical and clinical stage product pipeline. For more information, visit the company’s website at www.inovio.com